Terminal / Weight Loss

Survodutide

Phase 3

aka BI 456906

Dual GLP-1/glucagon agonist in phase 3 for obesity and fatty liver.

Mechanism

Activates GLP-1 and glucagon receptors: appetite down, energy expenditure up. The glucagon arm is also why it's being pushed hard for MASH, the serious fatty-liver disease.

Regulatory & Safety Status

Investigational (Boehringer Ingelheim and Zealand Pharma). Not approved.

Research

2026Indian journal of pharmacology

Pharmacological management of obesity: Current landscape and emerging therapies

2026Nature medicine

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

2026Journal of chromatography. A

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application

2026Diabetes therapy : research, treatment and education of diabetes and related disorders

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

2024PubMed

Latest survodutide research

Related Compounds

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.